The EU-funded HYMAGINE project has combined conventional electronic transistors with new magnetism-based ‘spintronic’ devices to improve information processing speeds and reduce energy consumption.
Caption: Automatic electrical testing of hybrid CMOS/magnetic chips from HYMAGINEDetails
Faster supercomputers demand ever smaller-scale microstructures if they are to remain on a rising performance curve. Yet as transistors shrink to the nanometre scale, so power densities and temperatures rise – and the materials they are made of can only take so much before breaking down.
HYMAGINE researchers have developed hybrid solutions combining conventional semiconductor (CMOS) components with memory devices based on magnetic tunnel junctions (MTJ). These logic/memory hybrids use much less energy than CMOS-only circuits. The magnetic memory works as fast as existing static random access memory (SRAM), but storage is more stable than SRAMs – just like in (much slower) hard disk drives.
A new spin on old technology
Basic MTJs have two magnetic layers separated by a thin layer of magnesium oxide. In one magnetic layer the magnetic polarity is fixed, in the other ‘free’ storage layer it can switch. The junction uses ‘spin transfer torque’ to write information, whereby electrons flowing in the device are ‘spin polarised’ and can switch the polarity in the storage layer between two (binary) states. Read operations rely on measuring the resistance through the MgO layer, which is higher with opposed polarities and lower with aligned polarities.
“When testing read/write operations in our junctions we investigated several important properties,” says Dieny. “First we demonstrated that CMOS/MTJ hybrids can operate at industry-standard speeds of around 1GHz. We found they consume a fifth of the energy needed by conventional all-CMOS systems, so they use significantly less power.
“A further critical property is the ‘endurance’ of the junction, which is the number of read/write voltage cycles it can support before failure becomes likely. Standard flash memory such as USB drives will support 100 000 cycles, but we found our hybrids have an endurance of 1015 cycles – almost unlimited for practical purposes!”
As endurance is such a critical property for eventual take-up, the HYMAGINE team investigated the physical mechanisms causing device failure. They found that electrons tunnelling through the MgO layer are trapped at lattice defects. Trapping and untrapping of electrons can lead to high stresses in the layer leading to early material breakdown.
“We established that the density of defects, such as incorporated water molecules, must be kept low. Already a number of equipment suppliers are adapting their vacuum equipment to reduce background H2O pressures with an eye on growing markets for MTJ devices,” explains Dieny. “We also found that the endurance of a newly manufactured device can be predicted using a measure of voltage background noise. This is a significant result for chip-makers who can use such measurements as quality control steps in volume manufacturing.”
HYMAGINE also developed advanced computer-based modelling and design tools for CMOS/MTJ hybrids and incorporated these into widely-used industry-standard software packages. Building on this work, a new company eVaderis was set up to offer spintronic design services, and eventually devices to the semiconductor world.
“There is too little communication between the ‘microelectronics’ and ‘magnetism’ communities in the semiconductor world, and this is holding back spintronic applications,” says Dieny. “This is why we launched annual summer schools in Grenoble on MRAM technologies – bringing researchers and engineers together to learn more about spintronics.”
Dieny is also taking spintronics further in a new ERC project called MAGICAL, which will add communications and sensor functions to low power CMOS/MTJ hybrids. “If the ‘Internet of Things’ is to advance, then low power devices are a must,” he explains. “Wearable computers, solar-powered sensors, connected pacemakers – they all demand low power solutions, and magnetism-based devices can offer these as HYMAGINE showed.”
Bernard Dieny’s achievement in the field of MRAMs was recognised with the award of the Adrien Constantin de Magny Prize by the French Académie des Sciences in 2015.Project details:Researcher (PI):Bernard DienyHost institution:Commissariat A L Energie Atomique Et Aux Energies Alternatives, FranceProject:Hybrid CMOS/Magnetic components and systems for energy efficient, non-volatile, reprogrammable integrated electronics, (HYMAGINE)ERC call:Advanced Grant , ERC-2009-AdG, panel PE7Max ERC funding:2,500,000 €Duration:Start date: 2010-07-01, End date: 2015-06-30
In an early application of a new discovery in semiconductor physics, EU-funded researchers have developed a silicon infrared detector that is simpler and cheaper than conventional detectors. The ultimate goal is a silicon-based laser.
© Portrait: Kevin Homewood
© Illustration: Ion Beam Centre, University of Surrey, Guildford, Surrey, GU2 5XH, UKDetails
All modern electronic devices use integrated circuits built on silicon. But silicon can’t do everything and one thing it cannot do is give out light. There are no silicon LEDs or lasers. It is rather better at detecting light, and can do so in the ultraviolet and visible regions of the spectrum, but fails in the near infrared, being unable to sense radiation longer than about 1.2 microns.
“Silicon is a very good detector in the visible and near infrared,” says Kevin Homewood of the University of Surrey, “but it lacks the ability to produce light efficiently.” Since 2009 Homewood’s team has been supported by the European Research Council in efforts to coax silicon into emitting light.
Why does this matter? There are two reasons. First, to make circuits that can emit or detect infrared light, manufacturers have to graft other materials onto silicon chips. Making it all in silicon would greatly simplify the process and reduce costs.
But the second and more important reason is that it would open the way to a silicon laser. Such a laser would make it possible to transmit signals within integrated circuits by light rather than by electrons and so replace electronic chips with faster and more efficient optical chips.
In a paper published in February 2016, Homewood and his colleagues described their discovery of “band-edge modification”, where small quantities of rare earth elements – notably europium, ytterbium and cerium – can be made to alter the electronic properties of silicon, allowing it to absorb and emit light out to mid-infrared wavelengths. “It’s completely new physics,” he says. “And it also has nice applications.”
Among those applications is, potentially, the long-sought silicon laser, but for the time being his group is concentrating on using the technique to develop infrared detectors.
“We decided the detector technology was closest to market,” he says. “We still have work to do on the laser – we’ve got close, but we’re not quite there – and will go back to it at some point. But the detector is something that’s almost usable now.”
The new silicon detector covers those parts of the mid-infrared spectrum – 1.6 to 6 microns – of most interest for sensing molecular gases such as carbon dioxide.
Conventional infrared detectors use toxic materials such as cadmium mercury telluride and need to be cooled with liquid nitrogen to operate efficiently. “We can potentially replace a lot of those materials with silicon which is non-toxic and also much cheaper and easier to manufacture,” Homewood says.
As the six-year ERC Advanced grant ended in 2014, the ERC awarded Homewood a further 18-month Proof-of-Concept grant to commercialise the detector technology. The Royal Society then followed with a two-year Brian Mercer Award for Innovation which Homewood, now working at Queen Mary University of London, is using to refine the technology to operate at or near room temperature. A new spin-out company is being set up to market the detectors.
It’s a big deal. The world market for mid-infrared detectors is estimated to grow to USD 5 billion by 2018, mainly in security and military thermal imaging applications but also in environmental monitoring.
Homewood says that the long-term support from the ERC allowed him to spend more of his time on the project than he would otherwise have done. “And because the ERC and the Royal Society are high prestige contracts it endorses the technology when you try to go out and get investors.
“We’ve got the patents pretty well pinned down and we’ve got some seed funding to develop a business plan that will enable us to go out and get some serious investment ready for the next stage.”Project details:Researcher (PI):Kevin Peter HomewoodHost institution:University Of Surrey, United KingdomProject:Silicon integrated lasers and optical amplifiers, (SILAMPS)ERC call:Advanced Grant , ERC-2008-AdG, panel PE7Max ERC funding:1,928,021 €Duration:Start date: 2009-01-01, End date: 2014-12-31
European researchers have identified a novel approach to prevent the growth of cancer tumours and inhibit them from spreading, potentially leading to highly effective treatments with fewer side effects.
© Portrait: Katie Van Geyte
© Illustration: Microscopic image of the PFKFB3 project – Results published in Cantelmo AR, et al., Cancer Cell 2016 Nov 8Details
The work, conducted in the ECMetabolism project with support from the European Research Council (ERC), builds on prior research into the formation of blood vessels – a process known as angiogenesis – that supply tumours with nutrients and oxygen. Blood vessels also provide a route for cancer to metastasise from the original tumour and spread elsewhere in the body.
Current anti-angiogenic therapies aim to destroy all tumour blood vessels and starve the cancer cells. But the treatment often provokes numerous side-effects, while its effectiveness can be inhibited by patient resistance and may even increase the risk of metastasis.
“There was an unmet need for novel anti-angiogenic strategies with fundamentally distinct mechanisms,” explains Peter Carmeliet, who led the ECMetabolism research at the VIB Vesalius Research Center of KU Leuven in Belgium. So the research team set out to develop a new anti-angiogenic concept targeting key metabolic pathways in endothelial cells which line the blood vessels, rather than the blood vessels themselves. “Our work has advanced the current state of the art and scientific understanding in the field of metabolism and angiogenesis.”
A little-known cell
When the ERC project began more than five years ago, very little was known about how endothelial cell metabolism regulates vessel sprouting, a process in which existing blood vessels grow offshoots that become new vessels. Carmeliet hypothesised that endothelial cell metabolism is the engine driving vessel sprouting and that turning down the engine in endothelial cells would provide an alternative anti-angiogenic treatment.
What is the key to turning down the engine? Glucose, more commonly known as blood sugar, which Carmeliet and his team identified as a major fuel source for endothelial cell metabolism through a process called glycolysis.
“We showed that endothelial cells are addicted to glycolysis, and that a partial and transient reduction of glycolysis by blocking the glycolytic activator PFKFB3 – using the commercially available small molecule compound, 3PO – inhibits pathological angiogenesis without systemic effects. To the best of our knowledge, these are the first findings showing that a metabolic pathway (glycolysis) can be a target for tumour vessel normalisation and anti-metastatic therapy,” Carmeliet says.
Crucially, in vitro and in vivo animal studies conducted by the ECMetabolism researchers showed that other cell types do not rely as much on glycolysis as endothelial cells and are therefore able to switch to alternative metabolic pathways, potentially resulting in far fewer side-effects for patients.
Following on from that ground-breaking research, Carmeliet and his team are now shifting focus towards translating the results into metabolic anti-angiogenic treatment candidates for new drugs, including screening a library of existing pharmaceutical compounds for an alternative PFKFB3 inhibitor that would be more active and easier to administer.
“The ERC grant gave us the freedom and trust to pursue innovative, high-risk/high-gain research at the frontline of life sciences, attracting a critical mass of researchers over a longer period of time and making significant progress that would not have been possible via other funding organisations,” Carmeliet says. “With this support we have been able to produce ground-breaking scientific insights and discoveries in an unexplored research field that will be of great benefit for the scientific community and clinical medicine.”Project details:Researcher (PI):Peter Frans Martha CarmelietHost institution:Vib, BelgiumProject:Targeting endothelial metabolism: a novel anti-angiogenic therapy, (ECMETABOLISM)ERC call:Advanced Grant , ERC-2010-AdG, panel LS2Max ERC funding:2,365,224 €Duration:Start date: 2011-05-01, End date: 2016-04-30
An ERC-funded project has significantly increased understanding of the crucial role that microorganisms in the gut play in maintaining health. The findings have since led to a patent, as well as a follow-on project that could one day steer the way to new targeted treatments for diseases, including cancer.
Image: FISH analysis performed by Sara Carloni, PhD: in situ staining of bacteria (in green) in the gut lumen. Nuclei stained in blue (dapi).Details
“Microorganisms present in the intestine, collectively called the gut microbiota, are essential to our health,” explains Maria Rescigno from the European Institute of Oncology in Italy, who led the DENDROworld project. “They break down larger molecules – like complex sugars – that we as humans are not equipped to degrade, enabling us to harvest more energy from food. They are also essential in the correct development of our immune system.”
However, alterations in microbiota composition – a condition called dysbiosis – have been associated with obesity, diabetes and cancer, although it is not yet clear whether dysbiosis is a cause or an effect of the disease. A key goal of the ERC-funded DENDROworld project was therefore to better understand exactly how microbiota is tolerated within the gut.
“We achieved two major results,” says Rescigno. “First, we found that epithelial cells –those that line the intestine – release a molecule called Thymic stromal lymphopoietin (TSLP) that comes in two flavours; a short isoform, which is responsible for the establishment of tolerance, and a long isoform, which is responsible for the establishment of inflammation.”
Rescigno and her team found that the short isoform is expressed in the healthy tissue, while the long isoform is expressed only in inflamed tissue such as in atopic dermatitis and ulcerative colitis. This discovery opens up the possibility of using the TSLP short peptide to fight inflammatory diseases by re-establishing immune tolerance. This finding has since been patented.
Secondly, the project discovered that the composition of microbiota is dependent on the amount and diversity of the mucosal immunoglobulin of the A type (IgA). “[This] is dependent on the amount of IgAs that is inherited and/or delivered by the mother through milk,” explains Rescigno. “This discovery has implications in the first phases of life, as it indicates that delivering IgAs early in life can positively impact microbiota diversity.”
As changes in microbiota composition have been associated with certain diseases, this finding could give new-born babies a ‘push’ in the right direction.
New research possibilities
The project’s success has enabled Rescigno to launch a second ERC-funded project, called HOMEOGUT, which relates to the patented findings on TSLP. “We wanted to go deeper into understanding the mechanisms of the short isoform,” she explains. “Here, we focus more on what it is that enables our body to avoid microbiota from spreading. How do we protect ourselves and prevent microbiota from entering the blood stream, for example?”
So far, the project has demonstrated the existence of a gut vascular barrier, similar in structure to the blood brain barrier that controls the flux of molecules capable of entering the host.
“We found that this barrier is disrupted in coeliac disease patients who have liver damage,” says Rescigno. “We therefore successfully demonstrated a link between the gut and the liver that can be disrupted by disease. We are now evaluating the barrier in other disorders and whether this can be a new target of intervention in several diseases, including cancer.”
Rescigno is excited about the potential impact that this line of research could have in terms of developing new therapeutic treatments, and is certain that the progress she has made would not have been possible without support from the ERC.
“These grants are so crucial because they provide you with a stable financial situation for long-term projects,” she says. “Having an ERC grant increases your chances of receiving other grants from national and international agencies, and I am now professor at the University of Milan, on the back of being an ERC awardee.”Project details:Researcher (PI):Maria RescignoHost institution:Istituto Europeo Di Oncologia Srl, ItalyProject:Mucosal dendritic cells in intestinal homeostasis and bacteria-related diseases, (DENDROWORLD)ERC call:Starting Grant , ERC-2007-StG, panel LS3Max ERC funding:1,195,680 €Duration:Start date: 2008-07-01, End date: 2013-06-30
When cancer is diagnosed in an expecting mother, the decision whether or not to start chemotherapy during the pregnancy needs to strike a delicate balance between the well-being of the mother and that of the foetus. With ERC support, Dr Frédéric Amant is developing a standard, integrated approach for cancer care for pregnant women.
Image: ©Ann De Wulf
Researcher image: ©Rob StevensDetails
Cancer in pregnancy is increasingly prevalent (1 to 2 in 2000 pregnancies in Europe), largely because of the recent trend to delay childbearing until a later age. While there is not yet evidence about the potential toxicity of chemotherapy on the foetus, as a precaution, this type of treatment has been largely avoided for pregnant women. Such approach generally led to delay in treatment, termination of pregnancy or premature induction of delivery.
In the last 50 years, drug regulation has significantly evolved. However, pregnant women and their foetuses remained out of scope, due to the general reluctance of pharmaceutical companies and expectant mothers to engage in dedicated drug trials. “This creates the need and the opportunity to investigate the true relationship between chemotherapy and childbearing with the objective of developing evidence-based rather than opinion-based decision-making", says Dr Frédéric Amant from the KU Leuven, in Belgium.
A pilot study led by Dr Amant back in 2012 showed that antenatal exposure to chemotherapy could overall be considered to be safe. This finding was internationally recognized as a first step towards a standard of care for women with cancer during pregnancy. With an ERC Consolidator grant and the support of a multidisciplinary team of experts, Dr Amant is now securing robust evidence about the risk/safety profile for foetuses under mothers’ chemotherapy:
Dr Amant: “The strength of our project lies in the integrated approach to this multifaceted problem of cancer in pregnancy, with two innovative methodological focus points: the use of an international patient registry of young women with cancer with a subregistry of women with pregnancy-associated breast cancer (the INCIP), along with the consultation of extensive biobanks. This allows for unprecedented large-scale clinical follow-up studies as well as laboratory studies on patient biomaterial.”
In addition, Dr Amant and his team foresee the application of cutting-edge models of human placental research to investigate the physiological basis of the placental barrier function. The researchers hope the study will be a major step forward to the well-being of both mother and foetus in a pregnancy complicated by cancer, leading to the development of standard diagnostic and therapeutic approaches during this critical period. In addition, the findings could provide substantial impetus to further research in this emerging field.Project details:Researcher (PI):Host institution:Katholieke Universiteit Leuven, BelgiumProject:Cancer treatment during pregnancy: from fetal safety to maternal efficacy, (CRADLE)ERC call:Consolidator Grants , ERC-2014-CoG, panelMax ERC funding:2,000,000 €Duration:Start date: 2015-10-01, End date: 2020-09-30
Over the past months, a sudden influx of ‘Pokémon Go’ players could be observed across the globe. Youngsters, people of all ages scrutinise their surroundings silently, using their smartphones to catch those digital creatures with unlikely names. How could such a phenomenon take over the world so fast? Part of the answer may be the game’s strong interaction with the real-world and its impressive mapping, offering a whole new virtual experience of spaces that seem to be familiar and yet so different.
Image & researcher picture: Courtesy S. LammesDetails
Based at the University of Warwick (UK), Sybille Lammes’ ERC-funded research focuses on digital mapping practices - including those related to play. She sees them as new media cultures that influence and alter our way of being and moving through spatial environments. She is also the first to combine New Media Studies, Science and Technology Studies and Human Geography and thereby to tackle an original and mostly unexplored research field.
“Digital maps can be simultaneously understood as new media, technologies and cartographies” explains Lammes, nourishing the conception of new media as “material cultures” that are physically embedded in daily life and technologies.
A new culture
Digital cartographies have changed the century-old conception of maps, traditionally perceived as something tangible representing a space. In the numerical world, on the other hand, we constantly interact with navigation and geolocation gadgets that are built in most applications and devices.
The maps of today are versatile real-time maps. Connected to online technologies – such as traffic sensors and GPS – they keep transforming before our eyes. Current navigation systems propose new routes when we miss a turn and adapt their suggestions to the way we play with them. We look for restaurants and shops through digital maps and some even date with the help of geolocation apps. Such daily tools influence our behaviour and thinking, the way we sense space and relate to it:
“The ambition of “Charting the Digital” is to define what digital mapping is about and what it culturally entails, and to explore, as a new techno-cultural phenomenon, its impact on our spatial relations”, says Lammes.
With her team, she has undertaken an extensive critical comparison of digital mapping practices, also in relation to traditional cartography and other related media forms. The research also encompasses the analysis of mapping interfaces, which act as technological mediators and induce users’ specific behaviour.
Sybille Lammes: “Our own research team members have become part of the study, by “going native”, i.e. becoming engaged and interacting with the material they study. They keep a journal about their experiences with the mapping interface and how they become acquainted with it”.
Digital mapping for playful learning
On the commercial side, Lammes’ team noted that highly successful and profitable digital mapping applications make use of a combination of gamification, connectivity and interactivity in their design. On this basis, they have developed a prototype of a location-based game: a mobile app named ‘Playfields’ that can be used to teach fieldwork to university students in a ‘hands on’ entertaining way.Project details:Researcher (PI):Sybille LammesHost institution:The University Of Warwick, United KingdomProject:Charting the Digital: Digital Mapping Practices as New Media Cultures, (Charting the Digital)ERC call:Starting Grant , ERC-2011-StG, panel SH5Max ERC funding:1,422,453 €Duration:Start date: 2011-11-01, End date: 2016-10-31
Despite recent advances in the fight against cancer, scientific research continues on several fronts. Current studies in the field of nanomedicine are proving very promising. Professor Valentina Cauda, from the Politecnico di Torino, has received funding from the European Research Council (ERC) for a pioneering project in this field, designed to develop therapies to target cancer cells without affecting the surrounding tissue.
Researcher picture: © Politecnico di TorinoDetails
What is your project about?
In my lab we design nanoparticles – known as TrojaNanoHorses (TNH) – which are engineered to be biomimetic, meaning that they can be injected into the bloodstream without causing immune reactions within the receiving body, that is, the tumour. The idea is that of the Greek myth of the Trojan Horse, which is not recognized as dangerous, hence is taken inside the city. Just like the horse, once inside the tumour cell, the nanoparticles give rise to mechanisms that can destroy it. In addition to this therapeutic effect, we have also designed the nanoparticles as diagnostic tools. In fact, when stimulated with ultraviolet lighting techniques, they will allow a better vision of the area affected by the tumour.
Currently there are many studies on this type of targeted treatment. What is the specificity of the nanoparticles you work with?
There are numerous and very valid studies carried out in recent years in the field of nanomaterials, materials of the dimensions of one billionth of a meter. Many of these involve the use of nanodrugs that are incorporated in the particle to be transported to the tumour cell. The difference of this project is that we do not foresee the use of chemotherapeutical substances associated with the nanoparticle. This should reduce the risks linked to the administration of these substances, in particular their unintentional release during the journey, which can damage other healthy tissues and organs. The therapeutic effect is due to a mechanism by which the nanoparticle disintegrates inside the tumour cell, releasing ions and radicals that damage it. Often, one hears of free radicals that are created by sunlight exposure and cause the ageing of cells. The procedure is very similar but, in this case, the release of radicals is extremely localized, and only occurs within the cancer cell.
Could this also be a valuable treatment for breast cancer?
The key to reaching the tumour is given by the molecules placed on the surface of the nanoparticle, which give the exact "address" to hit the target tumour cells. It will therefore be necessary to find the specific molecules to target breast cancer, in cooperation with clinicians and biologists with experience treating this type of tumour. It is essential, in fact, to find the peptide or antibody that binds to a specific receptor on the cancer cell, the selectivity otherwise fails and you can end hitting other cells. In general, it will be possible to extend these considerations to any type of cancer.
How will your project develop?
For the moment, the project is focused on the development of the nanoparticle in the lab. In the future, it will also cover the mechanisms of treatment and diagnosis on the tumour. During the next five years we will do studies on cultures of cancer cells in the lab and, if the data will be comforting, we can move on to clinical trials on patients, probably not before the next ten years.
How did you decide to specialise in nanomedicine?
Nanotechnologies have opened new horizons in various fields, as demonstrated by the recent Nobel Prize for chemistry about molecular machines. After my PhD, I started working with various groups that were working on nanoparticles for controlled drug delivery. Nanomedicine is an exciting interdisciplinary field, and without materials science, chemistry and physics, therapies may not be developed in an innovative and effective way. In Italy we are rather advanced in this field. In my group, eleven specialists from different disciplines work with me. They are all Italian, but we are trying to open up internationally thanks to an ERC initiative that will allow us to host researchers from around the world visiting an ERC laboratory.
Valentina Cauda is a chemical engineer. After obtaining her PhD in materials sciences in Italy, she worked at the University of Munich collaborating with various groups specialising in biomedical research. She decided to return to Turin initially at the Italian Institute of Technology and now, with ERC funding for her project, at the Politecnico di Torino, where she leads a research team.
Prof. Valentina Cauda and her team at Politecnico di Torino
Malgrado i recenti progressi nella lotta contro il cancro, la ricerca scientifica non si arresta e continua su vari fronti. Gli studi attualmente condotti nell’ambito della nanomedicina si stanno rivelando molto promettenti. La Prof.ssa Valentina Cauda, del Politecnico di Torino, ha ottenuto un finanziamento dallo European Research Council (ERC)per un progetto d’avanguardia in questo campo, mirato a sviluppare terapie che distruggono le cellule tumorali senza intaccare i tessuti circostanti.
In cosa consiste il suo progetto?
Nel mio laboratorio progettiamo delle nano-particelle - ribattezzate nano-Cavalli di Troia - che vengono ingegnerizzate per essere biomimetiche: questo significa che potenzialmente possono essere iniettate nel circolo sanguigno senza suscitare reazioni immunitarie nell'organismo che le riceve, cioè nel tumore. L'idea è quella del mito greco del Cavallo di Troia, che non essendo riconosciuto come pericoloso, viene lasciato entrare nella città. Proprio come il cavallo, una volta all’interno della cellula tumorale, le nanoparticelle danno luogo a meccanismi che la distruggono. Oltre a questo effetto terapeutico, le abbiamo progettate anche come strumenti diagnostici. Infatti le nanoparticelle, stimolate con tecniche di illuminazione ultravioletta, permetteranno anche di visualizzare l'area tumorale colpita.
Per saperne di più:
Attualmente esistono già molte altre ricerche su questo tipo di trattamento. Qual è la specificità delle nanoparticelle che studiate?
Ci sono tantissime e validissime ricerche condotte già da diversi anni nel campo dei nanomateriali, materiali di dimensioni nanometriche (1 miliardesimo di metro). Molte di queste prevedono l'utilizzo di nano-farmaci che vengono incorporati nella particella per essere trasportati fino alla cellula tumorale. La differenza di questo progetto è che noi non prevediamo l'utilizzo di chemioterapici associati alla nanoparticella. Questo dovrebbe abbattere i rischi legati alla somministrazione di tali sostanze, in particolare il rilascio involontario durante il percorso, che rischia di danneggiare altri tessuti e organi sani. L'effetto terapeutico è dovuto ad un meccanismo per cui la nanoparticella si disintegra all'interno della cellula tumorale liberando ioni e radicali che la danneggiano. Si sente spesso parlare dei radicali liberi che si creano quando ci si espone alla luce solare e che causano l'invecchiamento delle cellule. Il procedimento è molto simile ma, in questo caso, il rilascio di radicali è estremamente localizzato, e avviene soltanto all'interno della cellula tumorale.
Si tratta di un trattamento valido anche per i tumori al seno?
La chiave per raggiungere il tumore è data dalle molecole poste sulla superficie della nanoparticella e che danno “l'indirizzo” esatto per andare a colpire le cellule tumorali bersaglio. Sarà quindi necessario trovare “l’indirizzo” specifico per il cancro alla mammella, in collaborazione con medici e biologi esperti in questo tipo di tumore. È fondamentale infatti trovare il peptide o l'anticorpo che si lega al recettore presente sulla specifica cellula tumorale, altrimenti viene a mancare la selettività e si va a colpire qualsiasi tipo di cellula. In generale sarà possibile estendere queste considerazioni a qualsiasi tipo di tumore.
Per saperne di più:
Come si svilupperà il suo progetto?
Il progetto per ora riguarda lo sviluppo della nanoparticella in laboratorio, quindi lo studio dei meccanismi di terapia e diagnosi sul tumore. Durante i prossimi cinque anni faremo studi su culture di cellule tumorali in laboratorio e, se i dati saranno confortanti, si potrà passare alla sperimentazione clinica sui pazienti ma non prima di una decina anni.
Come mai ha deciso di specializzarsi in nanomedicina?
Le nanotecnologie aprono nuovi orizzonti in vari campi, come ha dimostrato anche il recente Premio Nobel per la Chimica sulle macchine molecolari. Dopo il dottorato ho cominciato a lavorare con vari gruppi specializzati su nanoparticelle per il rilascio controllato dei farmaci. La nanomedicina è un campo appassionante perché è interdisciplinare, e senza la scienza dei materiali, la chimica e la fisica, le terapie non potrebbero esser sviluppate in modo innovativo ed efficace. In Italia siamo abbastanza all’avanguardia in questo campo. Nel mio gruppo lavorano undici persone specializzate in ambiti diversi. Sono tutti italiani, ma stiamo cercando di aprirci a livello internazionale grazie ad un’iniziativa dell'ERC che permetterà di ospitare ricercatori da tutto il mondo in visita a un laboratorio ERC.
Per saperne di più:
Valentina Cauda è un ingegnere chimico. Dopo aver ottenuto il dottorato in scienza dei materiali in Italia, ha lavorato all’Università di Monaco di Baviera collaborando con vari gruppi attivi nella ricerca biomedica. Ha deciso di tornare a Torino prima presso l’Istituto Italiano di Tecnologia e ora, con il finanziamento del progetto ERC, presso il Politecnico di Torino dove dirige un’équipe di ricerca.Project details:Researcher (PI):Valentina CaudaHost institution:Politecnico Di Torino, ItalyProject:Hybrid immune-eluding nanocrystals as smart and active theranostic weapons against cancer, (TROJANANOHORSE)ERC call:Starting Grant , ERC-2015-STG, panelMax ERC funding:1,489,219 €Duration:Start date: 2016-03-01, End date: 2021-02-28
By focusing on certain actions and reactions within the brain, an EU-funded project has advanced understanding of how Alzheimer’s Disease develops. This could potentially open the door to a new era of targeted treatments.
Alzheimer’s Disease (AD) is the most common form of dementia, with symptoms that include gradually worsening memory loss and confusion. While there is no cure at present, a project funded by the European Research Council has opened up new research avenues that could one day lead to new therapeutic applications.
“Scientists have begun to better understand the genetics behind AD,” says MIRNA_AD project coordinator Bart De Strooper from VIB in Belgium. “For example, some 25 genes have been identified that we now know influence the genetic risk of developing the disease. We also know that amyloid peptides (a type of amino acid) are the main component of the amyloid plaques found in the brains of Alzheimer patients.”
Scientists believe that this plaque build-up blocks cell-to-cell signalling and could trigger inflammation. “What we don’t know, however, is exactly how Alzheimer’s progresses,” he adds.
Understanding disease pathways
De Strooper argues that the conventional focus on targeting amyloid peptides has been too simplistic. “It is based on the prediction that if you take away the amyloids, then you’ll have the cure,” he says. “The truth is that the development of AD is far more complex. It is not like killing the microbe that gives you pneumonia; AD involves a series of abnormal processes in the brain. What is needed is a new, non-linear way of thinking about how actions and reactions in the brain contribute towards the development of AD. We know now, for example, that abnormalities in amyloids start decades before the disease develops.”
The ERC grant enabled De Strooper to think outside of the box, and as a result make some important discoveries. “Our overall focus was on identifying pathways in the development of Alzheimer’s,” he explains. “We began by looking at both proteins and non-coding RNA (molecules involved in various biological roles in the expression of genes, but which are not translated into proteins), and examined the role that non-coding RNA might play in the development of AD.”
Potential therapeutic targets
The project was able to characterise important changes that take place in RNA in the brain of AD patients. In particular, De Strooper and his team identified several specific RNA molecules that changed significantly, such as the molecule micro-RNA 132. The next stage was then to investigate how these changes affect the brain in AD patients.
“By studying these micro-processes, we have arrived at a broader view of how AD develops, and achieved a broader understanding of what is going on in the brains of patients,” says De Strooper. “We now know that certain micro-RNAs regulate the amyloid and the Tau pathway together and could have an influence in inflammatory aspects of AD.”
These discoveries have opened up new research avenues. De Strooper is currently exploring whether micro-RNA molecules could be a potential target for therapeutic drugs, through studying the effect of manipulating these micro-RNA in mice. “It is perhaps a little early to say, but I think this research has the potential to be spun off one day and commercialised.”
The project has also underlined the complexity of Alzheimer’s, and the need to take a more holistic approach to research. “This is really where the ERC grant came into its own,” says De Strooper. “It can be difficult to get funding for this type of project, because they are seen as too speculative and risky. But the ERC is all about removing barriers and taking risks. The grant enabled me to carry out complex and efficient research, and I was able to train people who have since gone on to take up excellent positions.”Project details:Researcher (PI):Bart Geert Alfons Paul De StrooperHost institution:Vib, BelgiumProject:Role of microRNA dysregulation in Alzheimers Disease, (MIRNA_AD)ERC call:Advanced Grant , ERC-2010-AdG, panel LS5Max ERC funding:2,500,000 €Duration:Start date: 2011-05-01, End date: 2016-04-30
Many industries – and each of our cells – depend on emulsions. An EU-funded researcher has developed a method for studying molecules at the interface between oil nanodroplets and the water-based liquid contained in these substances. Her work advances understanding of liquid interfaces and emulsion stability, and is of great interest to industry.
Emulsions are mysterious phenomena – at the molecular level, at least. Found in industrial products such as lubricants, foods such as milk and in each of our cells, emulsions are made up of tiny droplets of one liquid that are dispersed in another.
The MINE project used an innovative spectroscopic light-scattering based method to study the molecules at the interface of these two liquids. This provides direct information about the molecules’ composition, orientation and environment – information that is useful for industry and developing new medicines.
“Our research can help us understand emulsions better and find better, cheaper ways to produce products,” says the project’s principal investigator, Sylvie Roke, head of the Laboratory for fundamental BioPhotonics at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. She adds: “Companies from different industrial sectors are very interested in our work.”
Understanding the interface structure and the mechanics of its formation could boost drug development and understanding how drugs interact with the body’s cells. It could also reduce manufacturing's need for surfactants – substances that help oil and water blend in products such as perfumes.
Although scientists already know that the composition and structure of these interface molecules determines an emulsions’ properties (such as stability and reactivity), until now they had no way to study them directly. Emulsions are liquids that contain moving droplets, and existing molecular probes cannot reach or are not sensitive enough to focus on the one-molecule-thick interface layers around the droplets.
MINE’s method – developed by Roke – overcomes this barrier and has produced new information about how these molecules organise themselves.
The method combines non-linear optics and light scattering. Non-linear optics uses infrared laser light that lets molecules vibrate at the surface of a droplet. The vibrating electrons in the molecules allow the emission of light particles (known as photons) of a specific colour – but only when the molecules are at the droplet/liquid interface.
This light travels in a specific direction, measured by light scattering. It contains unique information about the composition of the interface – which molecules are present, how they are organised and whether they interact with water.
By analysing this information, Roke was able to update scientific views on liquids and especially emulsions. One fundamental question concerns charge: droplets or air bubbles in water move towards a positive electrode. This means they possess a negative charge. The common explanation is that hydroxide ions in the liquid are the source of this charge, yet Roke found this is incorrect, finding no such ions on droplet surfaces.
She also found that charged surfactants – that protect the fatty oil droplets from the water – form very different structures than traditionally expected. Rather than forming a film of densely packed molecules around the droplets, they form dilute films with only a surfactant molecule here and there.
These results are unexpected, says Roke. “But since we are not assuming anything, and these are direct measurements, they open up a new understanding of soft nanoscopic systems, which include emulsions. This will also be useful for other branches of nanotechnology, for example it will help to tailor food products that also have biological functions, for our health.”
MINE was fully funded with a starting grant from the European Research Council. “The funding was fantastic,” says Roke. “Building this technology was high risk/high gain and took a long time to get right. The ERC grant gave me time to answer fundamental questions.”
She and her team are now helping other labs to implement her techniques and models. She is also adapting her technique to study water droplets that are billionths of a metre across. “This will teach us more about how water behaves in small spaces, which is relevant for understanding the molecular architecture of our own bodies”Project details:Researcher (PI):Sylvie RokeHost institution:Ecole Polytechnique Federale De Lausanne, SwitzerlandProject:Molecular Interfacial structure and dynamics of Nanoscopic droplets in Emulsions (MINE), (MINE)ERC call:Starting Grant , ERC-2009-StG, panel PE4Max ERC funding:1,150,000 €Duration:Start date: 2009-11-01, End date: 2014-10-31
While on court, beach volleyball players need to act as a whole in order to prevent the ball from touching the sand: in a fraction of a second - just before the opponent's hand spikes the ball - the passer has to predict and adjust to the attacker's action as well as to their teammate's block position. Thanks to her Consolidator Grant, cognitive science professor Natalie Sebanz is studying the cognitive and psychological mechanisms underlying joint action expertise – in other words, how individuals learn skilled actions, such as those performed by professional athletes, together.Details
Many human achievements, from planning and executing architecture plans to performing surgeries, piano duets and tangoes, are the result of collaboration. According to Prof. Sebanz, teamwork is key for the advancement of human civilisation and heavily relies on joint actions. These occur whenever two or more people interact with one another to coordinate a particular action in space and time, in order to accomplish a shared goal.
Although philosophers agree that joint actions require shared intentions, debate on what shared intentions are is still ongoing. Besides, intending to do something together is clearly not enough to meet a target: "Imagine if a football team were to spend hours talking about how they will score a goal.There would be no guarantee that they would eventually manage to do so. This is why cognitive psychology and cognitive neuroscience are necessary to understand the mechanisms that come into play when people act together and allow for the fine-grained, timely coordination we see in team sports", explains Prof. Sebanz.
According to her research, members of a team rely on a variety of mechanisms to coordinate their actions. One crucial aspect is that, rather than focusing on their own specific movements, the team members mainly rely on the interaction with each other. Joint action expertise also involves planned coordination: "Take synchronous swimmers – their planned actions have to include their own contribution as well as their partners'. They all have an image of what their moves will look like when performed together. Being driven by this kind of mental imagery helps them to be so coordinated."
Prof. Sebanz's research also demonstrates that participation in highly coordinated activities boosts the participants’ sense of commitment: "The more athletes depend on each other, the more they feel bound to go on doing their part even though they are exhausted, like members of a rowing team who are running out of energy". This concept might also be the reason why rugby teams are so tightly knit – players value the group's performance and welfare more than their individual contribution.
In the project, Prof. Sebanz’s team also explores the benefits of joint improvisation. "Practising with exercises used in improvisational theatre, where participants cannot easily guess their partners’ intentions, may help team players to become more attuned to each other, while being confronted with an activity that is outside their field of expertise", concludes Prof. Sebanz.
The project, which started in 2014, uses electroencephalography along with behavioural and physiological indicators, such as measures of movement trajectories and heart rate synchronization. In the long term,
it may help develop autonomous robots designed to collaborate with humans and provide new therapies, based on social training interventions, to alleviate social disorders such as autism.Project details:Researcher (PI):Natalie SebanzHost institution:Kozep-Europai Egyetem, HungaryProject:Joint action expertise: Behavioral, cognitive, and neural mechanisms for joint action learning, (JAXPERTISE)ERC call:Consolidator Grants , ERC-2013-CoG, panel SH4Max ERC funding:1,992,331 €Duration:Start date: 2014-08-01, End date: 2019-07-31